| BRIEF COMMUNICATION |
|
| Year : 2017 | Volume
: 9
| Issue : 2 | Page : 87-89 |
|
|
Nilotinib-induced keratosis pilaris associated with alopecia areata and eyebrow thinning
Maya Halabi Tawil1, Rana El Khoury1, Roland Tomb1, Marwan Ghosn2
1 Department of Dermatology, School of Medicine, Saint-Joseph University, Hotel Dieu de France University Hospital and Medical Center, Beirut, Lebanon
2 Department of Oncology and Hematology, School of Medicine, Saint-Joseph University, Hotel Dieu de France University Hospital and Medical Center, Beirut, Lebanon
Correspondence Address:
Rana El Khoury
Hotel-Dieu de France, A. Naccache Avenue, Achrafieh, 166830 Beirut
Lebanon
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijt.ijt_1_17
|
|
|
Tyrosine kinase enzymes are an attractive target for anticancer therapies. Tyrosine kinase inhibitors (TKI) are well tolerated; somehow severe systemic side effects are rarely seen during treatment. Toxicities of skin and appendages may lead to poor compliance, psychosocial inconvenience, and drug interruption. Changes of the hair can arise following cures with TKI. Nilotinib, a second-generation TKI, has been responsible for various cutaneous side effects including different clinical presentations of alopecia (scarring and nonscarring forms). This paper reports the case of a 45-year-old male diagnosed with chronic myelogenous leukemia (CML) treated with nilotinib, who presented with a keratosis pilaris (KP)-like eruption, autoresolutive alopecia areata plaque of the wrist and diffuse eyebrow thinning. To date, eight cases of nilotinib-induced KP were reported. However, none of them was associated with alopecia areata. Hence, physicians need to be aware of this new cutaneous side effect and investigating the reason of this phenomenon requires additional studies.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
